From Name:
From Email:
To Name:
To Email:

Optional Message:


FDA puts clinical hold on Advaxis' cervical cancer vaccine

from FierceVaccines

On Sept. 18, Advaxis reported "encouraging" data from a Phase II trial of its cervical cancer vaccine, axalimogene filolisbac, dubbed ADXS-HPV. Now, the biotech is reporting an FDA clinical hold on the candidate. The hold affects four studies involving ADXS-HPV. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063